Opdivo trial stopped early as BMS med tops Afinitor in kidney cancer

Bristol-Myers Squibb ($BMY) hit a big milestone in its quest to expand use of the immunotherapy Opdivo in a slate of cancer types. In a late-stage kidney cancer study, Opdivo showed a survival advantage over Novartis' ($NVS) Afinitor, prompting a monitoring committee to stop the trial early. Release